Anti-pyroglutamic acid-modified amyloid beta protein antibody and its use

By developing specific antibodies against pyroglutamate-modified amyloid protein (AβpE3-42), the problem of insufficient antibody affinity in the prior art was solved, and effective diagnosis and treatment of Alzheimer's disease was achieved, showing that Stronger specific binding ability.

CN118459582BActive Publication Date: 2024-11-15NOVOPROTEIN SCI INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410926229.1
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-07-11
Publication Date
2024-11-15
Estimated Expiration
2044-07-11

AI Technical Summary

Technical Problem

The existing technology is difficult to effectively treat β-amyloid protein (AβpE3-42) modified by Alzheimer's disease, and the existing antibody affinity is insufficient, so it cannot be effective in the Alzheimer's disease transgenic mouse model. Brain sections specifically bind.

Method used

An anti-pyroglutamate-modified beta amyloid protein (AβpE3-42) antibody was developed, including specific heavy and light chain variable region amino acid sequences, and a high affinity antibody was obtained through immune technology, capable of specifically binding to AβpE3. -42 polypeptide and is used to prepare diagnostic, preventive and therapeutic products.

Benefits of technology

The obtained antibodies can efficiently and specifically bind brain sections of transgenic mouse models of Alzheimer's disease, with higher affinity than antibodies in the prior art, showing stronger neuronal cytotoxicity and diagnostic potential.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118459582B_ABST
    Figure CN118459582B_ABST
Patent Text Reader

Abstract

The present invention relates to the field of antibodies, and in particular to an anti-pyroglutamate-modified amyloid beta antibody and its use. The CDR of the heavy chain variable region in the anti-pyroglutamate-modified amyloid beta antibody provided by the present invention comprises a CDR-H1 with an amino acid sequence such as SEQ ID No.2, a CDR-H2 with an amino acid sequence such as SEQ ID No.3, and a CDR-H3 with an amino acid sequence such as SEQ ID No.4; an anti-Aβ pE3‑42 The CDR of the light chain variable region in the antibody includes CDR-L1 as shown in the amino acid sequence of SEQ ID No.6, CDR-L2 as shown in the amino acid sequence of SEQ ID No.7, and CDR-L3 as shown in the amino acid sequence of SEQ ID No.8. The antibody provided by the present invention has high antibody affinity and anti-pyroglutamic acid-modified amyloid beta protein antibody, which can specifically bind to the brain slices of the Alzheimer's disease transgenic mouse model (5xFAD), and has a higher affinity than the anti-Aβ in the prior art. p3‑42 Antibody.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of antibodies, and in particular to an antibody against pyroglutamic acid-modified amyloid beta protein and uses thereof. Background Art

[0002] β-amyloid protein (Aβ) contains 39 to 43 amino acids and has a molecular weight of about 4kDa. It is a fragment hydrolyzed from β-amyloid precursor protein (APP). It can be produced by a variety of cells and circulates in the blood, cerebrospinal fluid, and interstitial fluid. Most Aβ is bound to chaperone protein molecules, and a few exist in a free state. Aβ is highly conserved in the evolutionary process and plays a key role in maintaining the homeostasis of the central nervous system. Aβ has Aβ 1-40 , Aβ 1-42 Two main types and other less common types: Aβ 1-42 It is a β-sheet structure with strong hydrophobicity, easy to deposit and aggregate, thus forming the core of Aβ precipitation, which is neurotoxic. Under normal circumstances, 90% of the human body is Aβ. 1-40 , only a small amount of Aβ 1-42 Yes. Due to genetic and other factors, Aβ in the brain of patients with Alzheimer's disease (AD) 1-42 / Aβ 1-40 Imbalance, Aβ 1-42 Increased. The Aβ monomers produced aggregate into Aβ oligomers, Aβ fibrils, Aβ fiber aggregates and other forms, and can change conformation to become plaques, mediating AD through various mechanisms. Increased Aβ 1-42 Deposition in the brain to form the core of senile plaques can activate microglia, trigger inflammatory reactions, and activate cell apoptosis pathways, mediate cell apoptosis, and promote abnormal phosphorylation of Tau protein by activating protein kinases. These pathological changes can promote the increase of Aβ production and abnormal deposition, produce a positive feedback cascade amplification effect, and ultimately lead to a decrease in neurons, abnormal transmitters, and clinical cognitive and behavioral symptoms. A few types of β-amyloid protein (Aβ), such as Aβ 1–43 and pyroglutamylated Aβ 3–42 It is involved in the initiation of the Aβ aggregation process and is closely related to the etiology of Alzheimer's disease.

[0003] Extracellular plaques of amyloid β (Aβ) and intraneuronal neurofibrillary tangles formed by tau protein are the histopathological features of Alzheimer's disease (AD). Plaques contain Aβ fibrils assembled from monomers and oligomeric intermediates and are a prognostic indicator of AD. Oligomers are the main toxic form of Aβ. The N-terminal truncated, pyroglutamylated (pE) form of Aβ is closely associated with AD and is more likely to be involved in AD than Aβ.1-40 , Aβ 1-42 It is more toxic and is considered to be a trigger for the onset of AD.

[0004] N-terminally truncated and pyroglutamate-modified amyloid beta (Aβ) plays a major role in the development of Alzheimer's disease. This pyroglutamate-modified amyloid beta is also called Aβ pE3-42 , pE3-A, N3pG, N3pGlu. The post-translational formation of pyroglutamate (pGlu) at position 3 or 11 of Aβ implies cyclization of the N-terminal glutamate residue, making the modified peptide resistant to degradation, more hydrophobic, and prone to aggregation. Aβ pE3-42 It is present in Alzheimer's disease amyloid deposits and is the core of AD amyloid. pE3-42 Can be combined with excess Aβ 1‐42 co-oligomerizes to form misfolded metastable low-n oligomers (LNOS), which are similar to those composed only of Aβ 1‐42 Compared with similar LNOS generated by Aβ, LNOS is more cytotoxic to cultured neurons and can promote the generation of new LNOS. pE3-42 The unique ability of this protein has made it a new potential drug target for AD. Summary of the invention

[0005] In view of the above-mentioned shortcomings of the prior art, the object of the present invention is to provide a β-amyloid protein (Aβ) resistant to pyroglutamate modification pE3-42 ) Antibodies and uses thereof are used to solve problems in the prior art.

[0006] In order to achieve the above-mentioned and other related purposes, the present invention provides an anti-Aβ pE3-42 Antibodies, the anti-Aβ pE3-42 The antibody comprises a heavy chain variable region and a light chain variable region, and the anti-Aβ pE3-42 The antibody has one or more of the following technical features:

[0007] 1) The complementarity determining region of the heavy chain variable region includes CDR-H1 with the amino acid sequence shown in SEQ ID No. 2;

[0008] 2) the complementarity determining region of the heavy chain variable region includes CDR-H2 with the amino acid sequence shown in SEQ ID No. 3;

[0009] 3) the complementarity determining region of the heavy chain variable region includes CDR-H3 with the amino acid sequence shown in SEQ ID No. 4;

[0010] 4) the complementarity determining region of the light chain variable region includes CDR-L1 with the amino acid sequence shown in SEQ ID No. 6;

[0011] 5) the complementarity determining region of the light chain variable region includes CDR-L2 with the amino acid sequence shown in SEQ ID No. 7;

[0012] 6) The complementarity determining region of the light chain variable region includes CDR-L3 having an amino acid sequence as shown in SEQ ID No.8.

[0013] Preferably, the anti-Aβ pE3-42 The complementarity determining region of the heavy chain variable region of the antibody includes CDR-H1 with an amino acid sequence as shown in SEQ ID No.1, CDR-H2 with an amino acid sequence as shown in SEQ ID No.2, and CDR-H3 with an amino acid sequence as shown in SEQ ID No.3.

[0014] The present invention also provides an isolated polynucleotide encoding one or more of the following peptide segments:

[0015] 1) Anti-Aβ as described above pE3-42 The variable region of the heavy chain in an antibody;

[0016] 2) Anti-Aβ as described above pE3-42 The variable region of the light chain in an antibody;

[0017] 3) Anti-Aβ as described above pE3-42 Antibody.

[0018] The present invention also provides a nucleic acid construct, which contains the aforementioned isolated polynucleotide.

[0019] The present invention also provides an isolated engineered cell, wherein the engineered cell contains the aforementioned nucleic acid construct or the aforementioned polynucleotide.

[0020] The present invention also provides the aforementioned anti-Aβ pE3-42 Use of the antibody, the aforementioned polynucleotide or the aforementioned nucleic acid construct in preparing a product for disease diagnosis, prevention or treatment.

[0021] The present invention also provides a detection kit, which contains the aforementioned anti-Aβ pE3-42 Antibody.

[0022] As described above, an anti-Aβ pE3-42 Antibodies and uses thereof have the following beneficial effects:

[0023] The present invention uses Aβ pE3-42 Immunizing mice with peptides to obtain high-affinity anti-Aβ pE3-42 Antibodies, obtained against Aβ pE3-42 The antibody can specifically bind to brain slices of a transgenic mouse model of Alzheimer's disease (5xFAD) with higher affinity than existing anti-Aβ pE3-42 Antibody. BRIEF DESCRIPTION OF THE DRAWINGS

[0024] Figure 1 Shown is a diagram of the Aβ mouse antibody antigen differentiation detection results in the present invention.

[0025] Figure 2 Shown is a graph showing the results of antigen differentiation detection of Aβ humanized antibodies in the present invention.

[0026] Figure 3 The results show that the ELISA method of the present invention detects Aβ antibodies and Aβ pE3-42 Result diagram of peptide protein affinity.

[0027] Figure 4 Shown is the result of immunohistochemistry detection of Aβ humanized antibody in the present invention. DETAILED DESCRIPTION

[0028] The present invention provides a β-amyloid protein (Aβ) resistant to pyroglutamate modification pE3-42 ) antibody, the anti-Aβ pE3-42 The antibody comprises a heavy chain variable region and a light chain variable region, and the anti-Aβ pE3-42 The antibody has one or more of the following technical features:

[0029] 1) The complementarity determining region of the heavy chain variable region includes CDR-H1 with the amino acid sequence shown in SEQ ID No. 2;

[0030] 2) the complementarity determining region of the heavy chain variable region includes CDR-H2 with the amino acid sequence shown in SEQ ID No. 3;

[0031] 3) the complementarity determining region of the heavy chain variable region includes CDR-H3 with the amino acid sequence shown in SEQ ID No. 4;

[0032] 4) the complementarity determining region of the light chain variable region includes CDR-L1 with the amino acid sequence shown in SEQ ID No. 6;

[0033] 5) the complementarity determining region of the light chain variable region includes CDR-L2 with the amino acid sequence shown in SEQ ID No. 7;

[0034] 6) The complementarity determining region of the light chain variable region includes CDR-L3 having an amino acid sequence as shown in SEQ ID No.8.

[0035] In some embodiments, the anti-Aβ pE3-42The complementary determining region of the heavy chain variable region of the antibody includes CDR-H1 as shown in SEQ ID No.2, CDR-H2 as shown in SEQ ID No.3, and CDR-H3 as shown in SEQ ID No.4; or, the complementary determining region of the heavy chain variable region includes CDR-H1 as shown in SEQ ID No.6, CDR-H2 as shown in SEQ ID No.7, and CDR-H3 as shown in SEQ ID No.8.

[0036] In some embodiments, the anti-Aβ pE3-42 The complementary determining region of the heavy chain variable region of the antibody includes CDR-H1 as shown in SEQ ID No.2, CDR-H2 as shown in SEQ ID No.3, and CDR-H3 as shown in SEQ ID No.4, and the complementary determining region of the light chain variable region includes CDR-L1 as shown in SEQ ID No.6, CDR-L2 as shown in SEQ ID No.7, and CDR-L3 as shown in SEQ ID No.8.

[0037] In some embodiments, the anti-Aβ pE3-42 The antibodies are monoclonal antibodies.

[0038] In some embodiments, the anti-Aβ pE3-42 The amino acid sequence of the heavy chain variable region of the antibody includes:

[0039] a) an amino acid sequence as shown in one of SEQ ID No. 1 and 11; or

[0040] b) an amino acid sequence having 80% or more identity with the amino acid sequence shown in either SEQ ID No. 1 or 11 and having the function of the amino acid sequence defined in a).

[0041] Specifically, the amino acid sequence in b) specifically refers to an amino acid sequence as shown in one of SEQ ID No. 1 and 11 obtained by replacing, deleting or adding one or more (specifically 1-50, 1-30, 1-20, 1-10, 1-5, or 1-3) amino acids, or adding one or more (specifically 1-50, 1-30, 1-20, 1-10, 1-5, or 1-3) amino acids at the N-terminus and / or C-terminus, and having the function of the amino acid sequence as shown in one of SEQ ID No. 1 and 11. The amino acid sequence in b) may have 80%, 85%, 90%, 93%, 95%, 97%, or 99% or more identity with one of SEQ ID No. 1 and 11.

[0042] In some embodiments, the anti-Aβ p3-42 The amino acid sequence of the light chain variable region of the antibody includes:

[0043] c) an amino acid sequence as shown in one of SEQ ID No. 5 and 12; or

[0044] d) an amino acid sequence having at least 80% identity with the amino acid sequence shown in either SEQ ID No. 5 or 12 and having the function of the amino acid sequence defined in c).

[0045] Specifically, the amino acid sequence in d) specifically refers to an amino acid sequence as shown in one of SEQ ID No.5 and 12 obtained by substitution, deletion or addition of one or more (specifically 1-50, 1-30, 1-20, 1-10, 1-5, or 1-3) amino acids, or an amino acid sequence as shown in one of SEQ ID No.5 and 12 obtained by adding one or more (specifically 1-50, 1-30, 1-20, 1-10, 1-5, or 1-3) amino acids to the N-terminus and / or C-terminus, and having the function of the amino acid sequence as shown in one of SEQ ID No.5 and 12. The amino acid sequence in d) may have 80%, 85%, 90%, 93%, 95%, 97%, or 99% or more identity with one of SEQ ID No.5 and 12.

[0046] In some embodiments, the anti-Aβ pE3-42 The antibody comprises a peptide segment having an amino acid sequence of a heavy chain variable region as shown in SEQ ID No.1 and an amino acid sequence of a light chain variable region as shown in SEQ ID No.5; or a peptide segment having an amino acid sequence of a heavy chain variable region as shown in SEQ ID No.11 and an amino acid sequence of a light chain variable region as shown in SEQ ID No.12.

[0047] In some embodiments, the anti-Aβ pE3-42 The antibody further comprises a heavy chain constant region, i.e., a hIgG1 constant region, whose amino acid sequence is shown in SEQ ID No.9.

[0048] In some embodiments, the anti-Aβ pE3-42 The antibody further comprises a light chain constant region, namely a kappa chain constant region, whose amino acid sequence is shown in SEQ ID No.10.

[0049] In some embodiments, the anti-Aβ pE3-42 The antibody also contains a secretion signal peptide. Specifically, the secretion signal peptide is derived from DsbA, PelB, OmpA, TolB, MalE, lpp, TorA or HylA signal peptide. Wherein, the secretion signal peptide will be anti-Aβ pE3-42 The antibodies are directed to the periplasmic space of the host cells.

[0050] In some embodiments, the anti-Aβ pE3-42 The antibody contains a histidine tag. A histidine tag or polyhistidine tag is attached to the anti-Aβ pE3-42 A sequence of 2 to 20 histidine residues of an antibody. A histidine tag comprises 2 to 20 histidine residues, 5 to 15 histidine residues, 5 to 18 histidine residues, 5 to 16 histidine residues, 5 to 15 histidine residues, 5 to 14 histidine residues, 5 to 13 histidine residues, 5 to 12 histidine residues, 5 to 11 histidine residues, 5 to 10 histidine residues, 6 to 12 histidine residues, 6 to 11 histidine residues, or 7 to 10 histidine residues.

[0051] In some embodiments, the anti-Aβ pE3-42 Antibody against human Aβ pE3-42 Anti-mouse Aβ pE3-42 Antibody.

[0052] The present invention also provides an isolated polynucleotide encoding one or more of the following peptide segments:

[0053] 1) The aforementioned anti-Aβ pE3-42 the heavy chain variable region of an antibody;

[0054] 2) The aforementioned anti-Aβ pE3-42 the light chain variable region of an antibody;

[0055] 3) The aforementioned anti-Aβ pE3-42 Antibody.

[0056] The present invention also provides a nucleic acid construct, which contains the aforementioned isolated polynucleotide.

[0057] In some specific embodiments, the nucleic acid construct is constructed by inserting the isolated polynucleotide into the multiple cloning site of the expression vector. The expression vector can be transformed, transduced or transfected into the host cell so that the genetic material elements it carries are expressed in the host cell. The construct is a viral vector or a non-viral vector. For example, non-viral vectors include: plasmids, phagemids, cosmids, artificial chromosomes such as yeast artificial chromosomes (YAC), bacterial artificial chromosomes (BAC) or P1-derived artificial chromosomes (PAC), bacteriophages such as λ phage or M13 phage, and animal viruses. Viral vectors include: retroviruses (including lentiviruses), adenoviruses, adeno-associated viruses, herpes viruses (such as herpes simplex virus), poxviruses, baculoviruses, papillomaviruses, papillomaviruses (such as SV40). The vector may contain a variety of elements for controlling expression, including promoter sequences, transcription initiation sequences, enhancer sequences, selection elements and reporter genes. In addition, the vector may also contain a replication initiation site. The vector may also include components that assist it in entering the cell, including but not limited to viral particles, liposomes or protein shells.

[0058] The present invention also provides an isolated engineered cell, wherein the engineered cell contains the aforementioned nucleic acid construct or the aforementioned polynucleotide.

[0059] In the present invention, the engineered cell can be obtained by introducing the aforementioned nucleic acid construct into a host cell, or a cell having the aforementioned exogenous polynucleotide integrated into its genome is the engineered cell.

[0060] Any cell suitable for expression by an expression vector can be used as a host cell, for example, the host cell can be a prokaryotic cell, such as a bacterial cell, or a lower eukaryotic cell, such as a yeast cell, or a higher eukaryotic cell, such as a mammalian cell. The host cell includes many cell types, such as prokaryotic cells such as Escherichia coli or Bacillus subtilis, fungal cells such as yeast cells or Aspergillus, insect cells such as S2 Drosophila cells or Sf9, or animal cells such as fibroblasts, CHO cells, COS cells, NSO cells, HeLa cells, BHK cells, HEK 293 cells or human cells.

[0061] The present invention also provides the aforementioned anti-Aβ pE3-42 Use of the antibody, the aforementioned polynucleotide or the aforementioned nucleic acid construct in preparing a product for disease diagnosis, prevention or treatment.

[0062] In some embodiments, the disease is Alzheimer's disease.

[0063] In some embodiments, the preventive or therapeutic product is an antibody drug.

[0064] The present invention also provides a detection kit, which contains the aforementioned anti-Aβ pE3-42 Antibody.

[0065] The present invention also provides a method for treating Alzheimer's disease, comprising administering an effective amount of the aforementioned anti-Aβ p3-42 Antibody.

[0066] In the present invention, the term "complementarity determining region" or "CDR" generally refers to a region in an antibody that can form complementarity with an antigenic determinant in terms of spatial structure. The variability in an antibody is generally not evenly distributed throughout the variable region of the antibody. The heavy chain variable region and the light chain variable region of a monoclonal antibody generally have three hypervariable regions (HVRs), which can generally form complementarity with an antigenic determinant in terms of spatial structure, so the hypervariable region is also called a complementarity determining region (CDR), i.e., the heavy chain variable region generally includes three complementarity determining regions, i.e., HCDR1, HCDR2 and HCDR3, and the light chain variable region generally includes three complementarity determining regions, i.e., LCDR1, LCDR2 and LCDR3.

[0067] In the present invention, the term "monoclonal antibody" generally refers to a population of antibodies, wherein the antibodies included in the population are substantially identical (except for a few possible naturally occurring mutations). Monoclonal antibodies are generally directed against specific determinants on an antigen.

[0068] In the present invention, the term "identity" means that if two or more than two sequences have the same nucleotide or amino acid length and order, the sequences are identical. The percentage of identity usually describes the degree to which two sequences are identical, that is, usually describes the percentage of nucleotides corresponding to the same nucleotides of the reference sequence at the sequence position. In order to determine the degree of identity (identity%), the sequences to be compared are usually of the same length, that is, the length of the longest sequence in the sequences to be compared. For example, a first sequence consisting of 8 nucleotides is 80% identical to a second sequence consisting of 10 nucleotides comprising the first sequence. It can therefore be understood that, in the context of the present invention, the identity of a sequence preferably relates to the percentage of nucleotides or amino acids in the sequence having the same position in two or more sequences of the same length. Specifically, the "identity%" of two amino acid sequences or two nucleotide sequences can be determined by aligning the sequences for the best comparison purpose and comparing the amino acids or nucleotides at the corresponding positions, for example, a gap can be introduced in either sequence to best align with the other sequence. A gap is usually regarded as a non-identical position, regardless of its actual position in the pair. The "best alignment" is generally the alignment of two sequences that produces the highest percent identity. The percent identity is determined by the number of identical nucleotides in the compared sequences, i.e., % identity = number of identical positions / total number of positions x 100. Other known mathematical algorithms can also be used by those skilled in the art to determine the percent identity between two sequences.

[0069] In the present invention, the term "plasmid backbone" is generally a circular DNA molecule or a linear DNA molecule that can autonomously replicate and express the inserted target gene in the cell. The backbone plasmid may contain regulatory sequences such as promoters, replicons, transcription and translation start and stop codons. The backbone plasmid is usually connected to the target gene to form a complete expression vector that can express a specific output in the cell.

[0070] The following describes the embodiments of the present invention through specific examples, and those skilled in the art can easily understand other advantages and effects of the present invention from the contents disclosed in this specification. The present invention can also be implemented or applied through other different specific embodiments, and the details in this specification can also be modified or changed in various ways based on different viewpoints and applications without departing from the spirit of the present invention.

[0071] Before further describing the specific embodiments of the present invention, it should be understood that the scope of protection of the present invention is not limited to the specific embodiments described below; it should also be understood that the terms used in the examples of the present invention are for describing the specific embodiments rather than for limiting the scope of protection of the present invention; in the present specification and claims, unless otherwise expressly stated herein, the singular forms "a", "an" and "the" include plural forms.

[0072] When the embodiments give numerical ranges, it should be understood that, unless otherwise specified in the present invention, both endpoints of each numerical range and any numerical value between the two endpoints can be selected. Unless otherwise defined, all technical and scientific terms used in the present invention have the same meaning as those generally understood by those skilled in the art. In addition to the specific methods, equipment, and materials used in the embodiments, according to the grasp of the prior art by those skilled in the art and the record of the present invention, any methods, equipment, and materials of the prior art similar or equivalent to the methods, equipment, and materials described in the embodiments of the present invention can also be used to realize the present invention.

[0073] The nucleotide or amino acid sequence information used in the present invention is as follows:

[0074] SEQ ID No.1:

[0075] QVQLQQPGAELVRPGASVKLSCKTS GYTFTRY INWVKQRPGQGLEWIGN IYPSDSYS NYNHKFKDKATLTVDKSSSTAYMQLSSSTSEDSAVYYC TREGGRGEVY WGQGTTLTVSS

[0076] SEQ ID No.5:

[0077] DVVMTQTPLTLSVTIGQPASISCKSS QSLLYSNGKIY LNWLLQRPGQSPKRLIY LVS KLDSGVPDRFTGSGSGTDFTLKISRVEAEDLGVYYC VQT FGGGTKLEIKR

[0078] SEQ ID No.9:

[0079] ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

[0080] SEQ ID No.10:

[0081] TVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

[0082] SEQ ID No.11:

[0083] QVQLQESGPGLVKPSETLSLTCTTS GYTFTRY INWVRQPPGKGLEWIGN IYPSDSY SNYNHKFKDRATLSVDKSKNQASLNLDSVSAADTAIYYC TREGGRGEVY WGKGSTVTVSS

[0084] SEQ ID No.12:

[0085] DVQMTQSPSSLSASVGDRVTITCKSS QSLLYSNGKIY LNWLQQKPGKAPKRLIY LVS KLDSGVPSRFSGSGSGTDFTFTISSLQPEDIATYYC VQT FGPGTKVDIKR

[0086] Example 1 Anti-Aβ pE3-42 Antibody Preparation

[0087] To generate an antibody against human Aβ pE3-42The antibody was pretreated overnight at 37°C to form aggregates of N-terminally truncated and pyroglutamic acid-modified human amyloid β peptide 3-42 (Aβ pE3-42 ) 6-8 week old Balb / c female mice were immunized with antigens and immunized with standard peptide immunization procedures. After 3 immunizations, spleens were taken from mice and fused with SP2 / 0 cells using the BTX electrofusion system to produce hybridomas. The hybridoma supernatant was tested for Aβ using an indirect ELISA format. pE3-42 Peptide-coated ELISA plate and Aβ 1-40 , Aβ 1-42 Peptide cross-reactivity. Positive clones are only positive for Aβ pE3-42 Peptide coated ELISA plate reaction, not with Aβ 1-40 , Aβ 1-42 Peptide reaction. The candidate clones screened out are used to retrieve relevant antibody sequences through specific gene amplification technology.

[0088] The retrieved antibody sequence A42Ta's VH (amino acid sequence as shown in SEQ ID No.1) and VL (amino acid sequence as shown in SEQ ID No.5) were respectively constructed into a eukaryotic expression vector containing a hIgG1 (amino acid sequence as shown in SEQ ID No.9)-kappa (amino acid sequence as shown in SEQ ID No.10) constant region. VH and VL were co-transfected into freestyle 293F cells. After culturing for 3 to 7 days, the supernatant was collected and purified using a protein A column to obtain the antibody protein corresponding to A42Ta.

[0089] Among them, the CDRs sequence information in this embodiment is as follows (IMGT definition, listed separately as follows):

[0090] Table 1 Mouse anti-Aβ pE3-42 Antibody CDR sequences

[0091] name sequence SEQ ID NO: CDR1 GYTFTRY 2 CDR2 IYPSDSYS 3 CDR3 TREGGRGEVY 4 CDR1 QSLLYSNGKIY 6 CDR2 LVS 7 CDR3 VQT 8

[0092] Humanized anti-Aβ pE3-42 Antibody construction and expression:

[0093] The VH and VL of the full-length antibody A42Ta were selected for humanization to obtain the humanized antibody A42TaA. The VH (amino acid sequence as shown in SEQ ID No.11) and VL (amino acid sequence as shown in SEQ ID No.12) of the humanized antibody sequence A42TaA were constructed into a eukaryotic expression vector containing the hIgG1 kappa constant region, and VH and VL were co-transfected into freestyle 293F cells. After culturing for 3 to 7 days, the supernatant was collected and purified with a protein A column to obtain the antibody protein corresponding to A42TaA.

[0094] The antibody used in this example can be obtained by chemical synthesis or by decompilation into a nucleotide sequence based on the known amino acid sequence and then introduced into cells by homologous recombination.

[0095] Example 2 Aβ Antibody Antigen Differentiation Detection

[0096] This example mainly shows the interaction between Aβ antibodies and three Aβ antigens (Aβ pE3-42 , Aβ 1-42 , Aβ 1-40 Specifically, the enzyme-linked immunosorbent assay (ELISA) was used to detect the affinity of Aβ pE3-42 , Aβ 1-42 , Aβ 1-40 The antigen was coated at 3ug / ml, and the antibody was diluted 5-fold at 20ug / ml in 8 gradients. Finally, anti-human IgG (Fc specific)-peroxidase antibody goat anti-antibody (sigma, A0170) was added for incubation. After adding TMB, the color was developed. After adding 1M HCl to terminate the reaction, the OD450 reading was performed using a microplate reader. The results were plotted as an S curve as shown in the figure. Figure 1 , Figure 2 , Figure 3 and Table 2. The results showed that Aβ antibodies showed pE3-42 The specificity of the peptides and the three antibodies to Aβ pE3-42 The peptides have similar affinities.

[0097] Table 2 ELISA detection of Aβ antibodies and Aβ pE3-42 Peptide protein affinity EC50 display

[0098] <![CDATA[Anti-Aβ p3-42 ]]> A42Ta A42T Donezetimumab EC50(ug / mL) 0.006792 0.005796 0.005401

[0099] Example 3 Immunohistochemical detection of Aβ humanized antibody

[0100] This example mainly demonstrates the binding of Aβ antibodies to brain slices of a transgenic mouse model of Alzheimer's disease (5xFAD). Specifically, 3-5 µm coronal brain tissue slices were routinely dewaxed and hydrated; the slices were placed in a citric acid antigen repair solution and placed in a microwave oven for antigen repair (8 minutes on medium heat until boiling, 8 minutes off heat to keep warm, and 7 minutes on medium-low heat). During the entire process, it is necessary to prevent the repair solution from evaporating excessively and do not dry the slices; the slices were placed in a 3% hydrogen peroxide solution to cover all tissues, and incubated at room temperature in the dark for 25 minutes to block endogenous peroxidase; after the slices were slightly dried, circles were drawn around the tissue with a tissue pen, and 10% BSA blocking solution was added, and the blocking was performed at room temperature for 30 minutes; the blocking solution was gently shaken off, and the primary antibody working solution was added to the slices, and the slices were incubated overnight at 4°C in a humidified box; after the slices were slightly dried, peroxidase-labeled goat anti-human IgG (Fc-specific) secondary antibody working solution (Sigma, cat#A0170) was added, and the slices were incubated at room temperature for 50 minutes. Add DAB color working solution to the tissue, stain for about 5 minutes (control the degree of color development under the microscope), rinse the slice with water to stop color development; counterstain with hematoxylin stain for 3 minutes, rinse with water. Then differentiate with hydrochloric acid alcohol differentiation solution for 5 seconds, rinse with water, and finally use blueing solution to blue, rinse with tap water. Immerse in 75%, 85%, anhydrous ethanol I, anhydrous ethanol II, and n-butanol for 5 minutes each, and dehydrate with gradient ethanol. Transparent xylene I and xylene II for 5 minutes each, dry and seal. Staining results are shown in Figure 4 The results showed that A42TaA showed more brown-yellow spots after staining than didenazumab, with a darker color, indicating stronger binding ability.

[0101] The above examples are for the purpose of illustrating the embodiments disclosed by the present invention and are not to be construed as limiting the present invention. In addition, the various modifications listed herein and the variations of the methods in the invention are obvious to those skilled in the art without departing from the scope and spirit of the present invention. Although the present invention has been specifically described in conjunction with various specific preferred embodiments of the present invention, it should be understood that the present invention should not be limited to these specific embodiments. In fact, various modifications as described above that are obvious to those skilled in the art to obtain the invention should be included within the scope of the present invention.

Claims

1. An anti-Aβ pE3-42 Antibody, It is characterized in that The anti-Aβ pE3-42 The antibody comprises a heavy chain variable region and a light chain variable region, and the anti-Aβ pE3-42 The antibody has the following technical features: 1) The amino acid sequence of the complementarity determining region CDR-H1 of the heavy chain variable region is shown in SEQ ID No. 2; 2) The amino acid sequence of the complementarity determining region CDR-H2 of the heavy chain variable region is shown in SEQ ID No. 3; 3) The amino acid sequence of the complementarity determining region CDR-H3 of the heavy chain variable region is shown in SEQ ID No. 4; 4) The amino acid sequence of the complementarity determining region CDR-L1 of the light chain variable region is shown in SEQ ID No.6; 5) The amino acid sequence of the complementarity determining region CDR-L2 of the light chain variable region is shown in SEQ ID No. 7; 6) The amino acid sequence of the complementarity determining region CDR-L3 of the light chain variable region is shown in SEQ ID No.

8.

2. The anti-Aβ according to claim 1 pE3-42 Antibody, It is characterized in that The anti-Aβ pE3-42 The antibody may also contain one or more of the following characteristics: a) Anti-Aβ pE3-42 The amino acid sequence of the heavy chain variable region of the antibody is shown in SEQ ID No. 1, and the anti-Aβ pE3-42 The amino acid sequence of the light chain variable region of the antibody is shown in SEQ ID No. 5; b) Anti-Aβ pE3-42 The amino acid sequence of the heavy chain variable region of the antibody is shown in SEQ ID No. 11, and the anti-Aβ pE3-42 The amino acid sequence of the light chain variable region of the antibody is shown in SEQ ID No. 12; c) Anti-Aβ pE3-42 The antibody comprises a heavy chain constant region having an amino acid sequence as shown in SEQ ID No.9; d) The anti-Aβ pE3-42 The antibody further comprises a light chain constant region with an amino acid sequence as shown in SEQ ID No.

10.

3. An isolated polynucleotide, It is characterized in that The polynucleotide encodes the anti-Aβ according to any one of claims 1-2 pE3-42 Antibody.

4. A nucleic acid construct, It is characterized in that The nucleic acid construct contains the polynucleotide according to claim 3.

5. An isolated engineered cell, It is characterized in that The engineered cell contains the nucleic acid construct of claim 4 or the polynucleotide of claim 3.

6. The anti-Aβ compound according to any one of claims 1 to 2 pE3-42 Use of an antibody, a polynucleotide according to claim 3 or a nucleic acid construct according to claim 4 in preparing a product for diagnosing Alzheimer's disease.

7. A detection kit, It is characterized in that The detection kit contains the anti-Aβ as described in any one of claims 1-2 pE3-42 Antibody.